MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Emergency Medicine Journal

  • November 1, 2026
A Drug-Free Method for Reducing Acute Atraumatic Anterior Temporomandibular Joint Dislocation
  • Moojan Shabani Kakroudi
  • Atefeh Abdollahi
  • Fatemeh Rasooli
  • November 1, 2026

Objective: To assess the feasibility and safety of the Rasooli Technique, a lateral pterygoid muscle massage approach for reducing atraumatic anterior TMJ dislo

...more
2 min

Gut

  • November 1, 2026
Palmoplantar skin lesions and chest pain in a patient with Crohn’s disease
  • Ouwais Alkhateb
  • Racha Ftouni
  • Ossama Abbas
  • Fadi H Mourad
  • November 1, 2026

Objective: Identify the most likely diagnosis and describe the management reported for a patient with Crohn’s disease receiving infliximab. Approach: Clinical a

...more
2 min

Blood Cancer Journal

  • October 31, 2026
STAG2 Mutation Is Associated With Improved Posttransplant Survival in Acute Myeloid Leukemia After Low-Intensity Induction
  • Yu-Sung Chang
  • Hsin-An Hou
  • October 31, 2026

Objective: To externally evaluate a previously reported posttransplant survival score and its component factors in an independent Asian cohort undergoing transp

...more
3 min

Archives Of Toxicology

  • October 31, 2026
Refining Animal Research: Using ‘Omics Technologies to Connect NAMs with More Informative Regulatory Studies
  • Bennard van Ravenzwaay
  • Philip A. Botham
  • Sergio Leon Perez
  • David Rouquié
  • Philip Marx-Stoelting
  • Tewes Tralau
  • October 31, 2026

Objective: The article examines the objective, findings, and clinical context described in Refining Animal Research: Using ‘Omics Technologies to Connect NAMs w

...more

MDSpire News

  • October 30, 2026
FDA approves tildrakizumab for psoriatic arthritis
  • Mouj Hijazi
  • October 30, 2026
  • 3 min
  1. The FDA approved tildrakizumab-asmn for adults with active psoriatic arthritis, expanding its use beyond moderate-to-severe plaque psoriasis.
  2. The approval was supported by INSPIRE-1 and INSPIRE-2, phase 3 trials of tildrakizumab 100 mg in adults with active psoriatic arthritis.
  3. In a pooled analysis of 806 participants, week 24 ACR20 responses occurred in 38.8% of patients receiving tildrakizumab and 24.4% receiving placebo.
  4. Among participants with psoriasis affecting at least 3% of body surface area, 41.0% receiving tildrakizumab and 10.9% receiving placebo achieved at least 75% PASI improvement.
  5. The most common adverse reactions, each reported in at least 3% of patients with psoriatic arthritis, were upper respiratory tract infections and COVID-19.
...more

MDSpire News

  • October 30, 2026
FDA revises warnings on 3 estradiol patches
  • Mouj Hijazi
  • October 30, 2026
  • 3 min
  1. The FDA revised boxed warnings for Minivelle, Vivelle, and Vivelle-Dot, removing statements about cardiovascular disease, breast cancer, and probable dementia.
  2. Information about cardiovascular and breast cancer risks remains elsewhere in the prescribing information, and the boxed warning for endometrial cancer with unopposed systemic estrogen remains.
  3. The revised Vivelle-Dot label retains contraindications for current or prior breast cancer, deep vein thrombosis, pulmonary embolism, and arterial thromboembolic disease.
  4. The label advises considering therapy initiation in women younger than 60 years or within 10 years of menopause and notes uncertainty about applying WHI findings to other estrogen products or routes.
  5. The FDA reported that estradiol patch output doubled over 12 months and that no nationwide shortage was imminent, although localized supply difficulties persisted.
...more

MDSpire News

  • October 30, 2026
Monthly fasting cycles may be feasible in T2D
  • Andrea Surnit
  • October 30, 2026
  • 2 min

Objective: Evaluate the feasibility of monthly 5-day fasting-mimicking diet (FMD) cycles for people with type 2 diabetes (T2D) in primary care. Approach: Design

...more
2 min

MDSpire News

  • October 30, 2026
Top 10 evidence-based essentials in ObGyn
  • Kathryn Wighton
  • October 30, 2026
  • 4 min

Objective: The article examines the objective, findings, and clinical context described in Top 10 evidence-based essentials in ObGyn. Approach: Cervical screeni

...more
2 min

MDSpire News

  • October 30, 2026
High TIRADS may signal cancer despite benign cytology
  • Andrea Surnit
  • October 30, 2026
  • 3 min
  1. This retrospective, single-center study included 176 surgically treated patients with Bethesda II benign thyroid cytology and postoperative histopathology.
  2. Postoperative malignancy was identified in 20 patients (11%), while 156 patients (89%) had benign findings.
  3. Malignancy was found in 32% of patients with TIRADS classifications of 4 or greater, compared with 7% of those with lower classifications.
  4. TIRADS classifications of 4 or greater were associated with about 5.7 times the adjusted odds of malignancy, and each additional year of age with about 8% lower odds.
  5. The authors cautioned that the 11% malignancy rate reflects a selected surgical population and should not be generalized to all patients with Bethesda II nodules.
...more

MDSpire News

  • October 30, 2026
Pedicle freezing may aid distal femur salvage
  • Andrea Surnit
  • October 30, 2026
  • 4 min
  1. In this retrospective study, 31 patients with malignant distal femoral tumors underwent freezing tank–assisted pedicle freezing and were followed for a mean of 52.3 months.
  2. Limb preservation was achieved in 90% of patients, and local recurrence occurred in 10%; all recurrences involved surrounding soft tissue, not frozen bone.
  3. Estimated overall survival was 93% at 2 years and 82% at 5 years, while mean Musculoskeletal Tumor Society functional score was 87.7%.
  4. No nonunions were reported, but 9 patients had nononcologic complications and 9 underwent reoperation.
  5. The authors noted that the small, retrospective study lacked a comparison group and called for comparative studies against established reconstruction methods.
...more

The Medicine Maker

  • October 30, 2026
The Challenge of Scaling Cell and Gene Therapy
  • Mouj Hijazi
  • October 30, 2026
  • 6 min

Objective: The article presents Erik Vaessen’s perspective on manufacturing challenges for cell and gene therapies, including scale-up, process development, and

...more
2 min

The Analytical Scientist

  • October 30, 2026
The Unanswered Questions About Vitamins
  • October 30, 2026
  • 3 min

Objective: The article examines the objective, findings, and clinical context described in The Unanswered Questions About Vitamins. Approach: Research trajector

...more
2 min

The Analytical Scientist

  • October 30, 2026
The Hidden Source of Elevated Tau
  • October 30, 2026
  • 3 min

Objective: To assess whether selectively enriching brain-derived tau improves the ability of blood tests to distinguish Alzheimer’s disease from amyotrophic lat

...more
2 min

The Pathologist

  • October 30, 2026
Rethinking Pathology Access in Kenya
  • Jessica Allerton
  • October 30, 2026
  • 6 min
  1. Kenya has approximately 1 to 3 pathologists per million people, many concentrated in major cities, while shortages of histology laboratories and transport impede timely diagnosis.
  2. The modular network separates slide preparation, courier logistics, and remote pathologist review, allowing a small number of laboratories and pathologists to serve multiple sites.
  3. A centralized software platform coordinates hospitals, laboratories, and pathologists; the pilot reportedly reduced diagnostic turnaround times by 70% to 90%.
  4. Standardized protocols, reporting templates, peer review, and consensus reporting support consistency across the network, which has served 79 facilities.
  5. Local workforce training, locally generated diagnostic data, and African governance of health data are central to sustainable expansion and representative AI development.
...more

The Pathologist

  • October 30, 2026
Gold-Based Sensor Finds Bugs, Fast
  • October 30, 2026
  • 2 min

Objective: Develop a filtration-based diagnostic platform to detect low concentrations of bacteria and assess antibiotic susceptibility rapidly. Approach: Platf

...more
2 min

Kaiser Family Foundation

  • October 30, 2026
Medicare Part D Stand-Alone Plan Premiums Could Rise 50% to $51 Monthly in 2027 Without a Switch to Lower-Cost Coverage
  • kfftiffanyf
  • October 30, 2026

Objective: The article summarizes KFF projections of 2027 Medicare Part D premiums and cost-sharing requirements, including projected costs for enrollees who re

...more
2 min

Jama Network Open

  • October 30, 2026
Correction to the Author Byline and Corresponding Author Name
  • October 30, 2026

Objective: Correct a misspelling in the author and corresponding-author name for an Original Investigation on trauma-care resources and timely access for patien

...more
1 min

United States Department Of Health And Human Services

  • October 30, 2026
HHS Final Rule Updates Section 504 Regulations to Clarify Statutory Exclusions from Disability Coverage
  • Office for Civil Rights (OCR)
  • October 30, 2026

Objective: The article describes HHS’s final rule specifying that gender dysphoria not resulting from a physical impairment falls within the statutory exclusion

...more
2 min